Publication & Citation Trends
Most Cited Works
Publications
244 total
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
Cited by 409
OpenAlex
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial OA
Cited by 14
Semantic Scholar
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab PDF
Cited by 598
OpenAlex
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. OA
Cited by 38
Semantic Scholar
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis PDF
Cited by 4,623
OpenAlex
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Cited by 1,020
OpenAlex
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Cited by 455
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(117)
HER2/EGFR in Cancer Research
(88)
Cancer Treatment and Pharmacology
(88)
Advanced Breast Cancer Therapies
(39)
Breast Lesions and Carcinomas
(29)
Frequent Co-Authors
Affiliations
Goethe University Frankfurt
Hebron University
Novartis (Switzerland)
University of Udine
The Royal Melbourne Hospital